Literature DB >> 18618901

Sequential continual reassessment method for two-dimensional dose finding.

Ying Yuan1, Guosheng Yin.   

Abstract

It is common to encounter two-dimensional dose finding in phase I trials, for example, in trials combining multiple drugs, or in single-agent trials that simultaneously search for the maximum tolerated dose (MTD) and the optimal treatment schedule. In these cases, the traditional single-agent dose-finding methods are not directly applicable. We propose a simple and adaptive two-dimensional dose-finding design that can accommodate any type of single-agent dose-finding method. In particular, we convert the two-dimensional dose-finding trial to a series of one-dimensional dose-finding subtrials along shortened line search segments by fixing the dose level of one drug. We then conduct the subtrials sequentially. Based on the MTD obtained from the completed one-dimensional trial, we eliminate the doses that lie outside of the search range based on the partial order, and thereby efficiently shrink the two-dimensional dose-finding space. The proposed design dramatically reduces the sample size and still maintains good performance. We illustrate the design through extensive simulation studies motivated by clinical trials evaluating multiple drugs or dose and schedule combinations. Copyright (c) 2008 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2008        PMID: 18618901     DOI: 10.1002/sim.3372

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  22 in total

Review 1.  Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.

Authors:  Christophe Le Tourneau; Véronique Diéras; Patricia Tresca; Wulfran Cacheux; Xavier Paoletti
Journal:  Target Oncol       Date:  2010-04-02       Impact factor: 4.493

2.  Identifying a maximum tolerated contour in two-dimensional dose finding.

Authors:  Nolan A Wages
Journal:  Stat Med       Date:  2016-02-22       Impact factor: 2.373

3.  Adaptive clinical trial designs in oncology.

Authors:  Yong Zang; J Jack Lee
Journal:  Chin Clin Oncol       Date:  2014-12

4.  A Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities.

Authors:  Suyu Liu; Jing Ning
Journal:  Bayesian Anal       Date:  2013-09-09       Impact factor: 3.728

5.  A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.

Authors:  Liangcai Zhang; Ying Yuan
Journal:  Stat Med       Date:  2016-08-31       Impact factor: 2.373

6.  A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents.

Authors:  Thomas M Braun; Shufang Wang
Journal:  Biometrics       Date:  2010-09       Impact factor: 2.571

7.  Advances in Statistical Approaches Oncology Drug Development.

Authors:  Anastasia Ivanova; Gary L Rosner; Olga Marchenko; Tom Parke; Inna Perevozskaya; Yanping Wang
Journal:  Ther Innov Regul Sci       Date:  2014-01       Impact factor: 1.778

8.  Continual reassessment method for partial ordering.

Authors:  Nolan A Wages; Mark R Conaway; John O'Quigley
Journal:  Biometrics       Date:  2011-03-01       Impact factor: 2.571

9.  Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses.

Authors:  Lin Huo; Ying Yuan; Guosheng Yin
Journal:  Bayesian Anal       Date:  2012       Impact factor: 3.728

10.  A Generalized Continual Reassessment Method for Two-Agent Phase I Trials.

Authors:  Thomas M Braun; Nan Jia
Journal:  Stat Biopharm Res       Date:  2013-01-01       Impact factor: 1.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.